Hemostatic compositions

Abstract

The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.

1 . A hemostatic composition comprising:
 a) a biocompatible polymer in particulate form suitable for use in hemostasis; and   b) one hydrophilic polymeric component comprising reactive groups.   
     
     
         2 . The hemostatic composition according to  claim 1 , wherein the biocompatible polymer and the hydrophilic polymeric component are present in dry form. 
     
     
         3 . The hemostatic composition according to  claim 1 , wherein said biocompatible polymer suitable for use in hemostasis contains a member selected from the group consisting of a protein, a polysaccharide, a biologic polymer, a non-biologic polymer; and derivatives and combinations thereof. 
     
     
         4 . The hemostatic composition according to  claim 1 , wherein said biocompatible polymer suitable for use in hemostasis contains a protein selected from the group consisting of gelatin, collagen, albumin, hemoglobin, fibrinogen, fibrin, casein, fibronectin, elastin, keratin, and laminin; and derivatives and combinations thereof. 
     
     
         5 . The hemostatic composition according to  claim 1 , wherein said biocompatible polymer suitable for use in hemostasis contains a crosslinked protein, a crosslinked polysaccharide, a crosslinked biologic polymer, a crosslinked non-biologic polymer; or mixtures thereof. 
     
     
         6 . The hemostatic composition according to  claim 1 , wherein the hydrophilic polymer component is a polyalkylene oxide polymer. 
     
     
         7 . The hemostatic composition according to  claim 1 , wherein said hydrophilic polymeric component with reactive groups is a polyethylene glycol (PEG). 
     
     
         8 . The hemostatic composition according to  claim 1 , wherein the biocompatible polymer is crosslinked gelatin and the hydrophilic polymeric component is pentaerythritolpoly(ethyleneglycol)ether tetrasuccinimidyl glutarate. 
     
     
         9 . The hemostatic composition according to  claim 1 , provided in dry form in an administration container. 
     
     
         10 . A method of treating a patient, comprising administering to the patient a hemostatic composition according to  claim 1  for the treatment of an injury selected from the group consisting of a wound, a hemorrhage, a damaged tissue, a bleeding tissue, and a bone defect. 
     
     
         11 . A method of treating an injury selected from the group consisting of a wound, a hemorrhage, a damaged tissue, and a bleeding tissue comprising administering the hemostatic composition of  claim 1  to the injury. 
     
     
         12 . A method for producing a hemostatic composition according to  claim 1  comprising the step of mixing a biocompatible polymer suitable for use in hemostasis and one hydrophilic polymeric component comprising reactive groups in dry form. 
     
     
         13 . A kit comprising a hemostatic composition in dry form according to  claim 1  and a diluent for reconstitution of the hemostatic composition. 
     
     
         14 . A method for providing a ready to use form of a hemostatic composition according to  claim 1 , wherein the hemostatic composition is provided in a first syringe and a diluent for reconstitution is provided in a second syringe, the first and the second syringe are connected to each other, and the diluent is brought into the first syringe to produce a flowable form of the hemostatic composition. 
     
     
         15 . The hemostatic composition according to  claim 2 , wherein the biocompatible polymer and the hydrophilic polymeric component are present in mixed dry form. 
     
     
         16 . The hemostatic composition according to  claim 6 , wherein the polyalkylene oxide polymer is a PEG comprising polymer. 
     
     
         17 . The hemostatic composition according to  claim 6 , wherein the polyalkylene oxide polymer is a multi-electrophilic polyalkylene oxide polymer. 
     
     
         18 . The hemostatic composition according to  claim 6 , wherein the polyalkylene oxide polymer is a multi-electrophilic PEG. 
     
     
         19 . The hemostatic composition according to  claim 6 , wherein the polyalkylene oxide polymer is pentaerythritolpoly(ethyleneglycol)ether tetrasuccinimidyl glutarate. 
     
     
         20 . The hemostatic composition according to  claim 7 , wherein the hydrophilic polymeric component with reactive groups is a polyethylene glycol (PEG) comprising two or more reactive groups selected from succinimidylesters (—CON(COCH 2 ) 2 ), aldehydes (—CHO) and isocyanates (—N═C═O).